nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—ABCB1—Sorafenib—liver cancer	0.139	0.245	CbGbCtD
Fesoterodine—CYP2D6—Sorafenib—liver cancer	0.131	0.231	CbGbCtD
Fesoterodine—ABCB1—Doxorubicin—liver cancer	0.0845	0.149	CbGbCtD
Fesoterodine—CYP3A4—Sorafenib—liver cancer	0.0835	0.147	CbGbCtD
Fesoterodine—CYP2D6—Doxorubicin—liver cancer	0.0797	0.14	CbGbCtD
Fesoterodine—CYP3A4—Doxorubicin—liver cancer	0.0507	0.089	CbGbCtD
Fesoterodine—Gastrooesophageal reflux disease—Sorafenib—liver cancer	0.00919	0.0364	CcSEcCtD
Fesoterodine—Dry skin—Sorafenib—liver cancer	0.00552	0.0219	CcSEcCtD
Fesoterodine—Abdominal pain upper—Sorafenib—liver cancer	0.0055	0.0218	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Sorafenib—liver cancer	0.00531	0.0211	CcSEcCtD
Fesoterodine—Abdominal discomfort—Sorafenib—liver cancer	0.00499	0.0198	CcSEcCtD
Fesoterodine—Infestation NOS—Sorafenib—liver cancer	0.00464	0.0184	CcSEcCtD
Fesoterodine—Infestation—Sorafenib—liver cancer	0.00464	0.0184	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Sorafenib—liver cancer	0.00439	0.0174	CcSEcCtD
Fesoterodine—Urinary tract disorder—Sorafenib—liver cancer	0.00411	0.0163	CcSEcCtD
Fesoterodine—Urethral disorder—Sorafenib—liver cancer	0.00408	0.0162	CcSEcCtD
Fesoterodine—Cardiac disorder—Sorafenib—liver cancer	0.00387	0.0153	CcSEcCtD
Fesoterodine—Mediastinal disorder—Sorafenib—liver cancer	0.00375	0.0149	CcSEcCtD
Fesoterodine—Mental disorder—Sorafenib—liver cancer	0.00365	0.0145	CcSEcCtD
Fesoterodine—Dysgeusia—Sorafenib—liver cancer	0.00355	0.0141	CcSEcCtD
Fesoterodine—Angioedema—Sorafenib—liver cancer	0.00331	0.0132	CcSEcCtD
Fesoterodine—Cough—Sorafenib—liver cancer	0.00316	0.0126	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00307	0.0122	CcSEcCtD
Fesoterodine—Dry mouth—Sorafenib—liver cancer	0.00302	0.012	CcSEcCtD
Fesoterodine—Infection—Sorafenib—liver cancer	0.00294	0.0117	CcSEcCtD
Fesoterodine—Nervous system disorder—Sorafenib—liver cancer	0.0029	0.0115	CcSEcCtD
Fesoterodine—Skin disorder—Sorafenib—liver cancer	0.00288	0.0114	CcSEcCtD
Fesoterodine—Dry eye—Epirubicin—liver cancer	0.00283	0.0112	CcSEcCtD
Fesoterodine—Dry eye—Doxorubicin—liver cancer	0.00262	0.0104	CcSEcCtD
Fesoterodine—Dyspepsia—Sorafenib—liver cancer	0.00261	0.0103	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Sorafenib—liver cancer	0.00256	0.0101	CcSEcCtD
Fesoterodine—Fatigue—Sorafenib—liver cancer	0.00255	0.0101	CcSEcCtD
Fesoterodine—Constipation—Sorafenib—liver cancer	0.00253	0.01	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Sorafenib—liver cancer	0.00242	0.0096	CcSEcCtD
Fesoterodine—Urticaria—Sorafenib—liver cancer	0.00235	0.00933	CcSEcCtD
Fesoterodine—Abdominal pain—Sorafenib—liver cancer	0.00234	0.00928	CcSEcCtD
Fesoterodine—Hypersensitivity—Sorafenib—liver cancer	0.00218	0.00865	CcSEcCtD
Fesoterodine—Face oedema—Epirubicin—liver cancer	0.00215	0.00853	CcSEcCtD
Fesoterodine—Asthenia—Sorafenib—liver cancer	0.00212	0.00843	CcSEcCtD
Fesoterodine—Pruritus—Sorafenib—liver cancer	0.00209	0.00831	CcSEcCtD
Fesoterodine—Dry skin—Epirubicin—liver cancer	0.00204	0.0081	CcSEcCtD
Fesoterodine—Abdominal pain upper—Epirubicin—liver cancer	0.00203	0.00807	CcSEcCtD
Fesoterodine—Diarrhoea—Sorafenib—liver cancer	0.00203	0.00804	CcSEcCtD
Fesoterodine—Face oedema—Doxorubicin—liver cancer	0.00199	0.00789	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00196	0.00779	CcSEcCtD
Fesoterodine—Dizziness—Sorafenib—liver cancer	0.00196	0.00777	CcSEcCtD
Fesoterodine—Dry skin—Doxorubicin—liver cancer	0.00189	0.00749	CcSEcCtD
Fesoterodine—Abdominal pain upper—Doxorubicin—liver cancer	0.00188	0.00746	CcSEcCtD
Fesoterodine—Angina pectoris—Epirubicin—liver cancer	0.00187	0.00744	CcSEcCtD
Fesoterodine—Rash—Sorafenib—liver cancer	0.00187	0.00741	CcSEcCtD
Fesoterodine—Dermatitis—Sorafenib—liver cancer	0.00186	0.0074	CcSEcCtD
Fesoterodine—Headache—Sorafenib—liver cancer	0.00185	0.00736	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00182	0.00721	CcSEcCtD
Fesoterodine—Dysuria—Epirubicin—liver cancer	0.0018	0.00714	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Epirubicin—liver cancer	0.00179	0.00709	CcSEcCtD
Fesoterodine—Nausea—Sorafenib—liver cancer	0.00176	0.00698	CcSEcCtD
Fesoterodine—Angina pectoris—Doxorubicin—liver cancer	0.00173	0.00688	CcSEcCtD
Fesoterodine—Infestation—Epirubicin—liver cancer	0.00172	0.00681	CcSEcCtD
Fesoterodine—Infestation NOS—Epirubicin—liver cancer	0.00172	0.00681	CcSEcCtD
Fesoterodine—Urinary tract infection—Epirubicin—liver cancer	0.00167	0.00662	CcSEcCtD
Fesoterodine—Dysuria—Doxorubicin—liver cancer	0.00166	0.0066	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00165	0.00656	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Epirubicin—liver cancer	0.00162	0.00644	CcSEcCtD
Fesoterodine—Infestation NOS—Doxorubicin—liver cancer	0.00159	0.0063	CcSEcCtD
Fesoterodine—Infestation—Doxorubicin—liver cancer	0.00159	0.0063	CcSEcCtD
Fesoterodine—Urinary tract infection—Doxorubicin—liver cancer	0.00154	0.00612	CcSEcCtD
Fesoterodine—Urinary tract disorder—Epirubicin—liver cancer	0.00152	0.00603	CcSEcCtD
Fesoterodine—Oedema peripheral—Epirubicin—liver cancer	0.00152	0.00602	CcSEcCtD
Fesoterodine—Urethral disorder—Epirubicin—liver cancer	0.00151	0.00599	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Doxorubicin—liver cancer	0.0015	0.00596	CcSEcCtD
Fesoterodine—Eye disorder—Epirubicin—liver cancer	0.00144	0.00571	CcSEcCtD
Fesoterodine—Cardiac disorder—Epirubicin—liver cancer	0.00143	0.00567	CcSEcCtD
Fesoterodine—Urinary tract disorder—Doxorubicin—liver cancer	0.00141	0.00558	CcSEcCtD
Fesoterodine—Oedema peripheral—Doxorubicin—liver cancer	0.0014	0.00557	CcSEcCtD
Fesoterodine—Urethral disorder—Doxorubicin—liver cancer	0.0014	0.00554	CcSEcCtD
Fesoterodine—Mediastinal disorder—Epirubicin—liver cancer	0.00139	0.00551	CcSEcCtD
Fesoterodine—Mental disorder—Epirubicin—liver cancer	0.00135	0.00535	CcSEcCtD
Fesoterodine—Eye disorder—Doxorubicin—liver cancer	0.00133	0.00528	CcSEcCtD
Fesoterodine—Cardiac disorder—Doxorubicin—liver cancer	0.00132	0.00525	CcSEcCtD
Fesoterodine—Flatulence—Epirubicin—liver cancer	0.00132	0.00524	CcSEcCtD
Fesoterodine—Dysgeusia—Epirubicin—liver cancer	0.00131	0.00521	CcSEcCtD
Fesoterodine—Back pain—Epirubicin—liver cancer	0.0013	0.00514	CcSEcCtD
Fesoterodine—Mediastinal disorder—Doxorubicin—liver cancer	0.00128	0.00509	CcSEcCtD
Fesoterodine—Vision blurred—Epirubicin—liver cancer	0.00126	0.00501	CcSEcCtD
Fesoterodine—Mental disorder—Doxorubicin—liver cancer	0.00125	0.00495	CcSEcCtD
Fesoterodine—Flatulence—Doxorubicin—liver cancer	0.00122	0.00485	CcSEcCtD
Fesoterodine—Dysgeusia—Doxorubicin—liver cancer	0.00121	0.00482	CcSEcCtD
Fesoterodine—Vertigo—Epirubicin—liver cancer	0.0012	0.00478	CcSEcCtD
Fesoterodine—Back pain—Doxorubicin—liver cancer	0.0012	0.00476	CcSEcCtD
Fesoterodine—Palpitations—Epirubicin—liver cancer	0.00118	0.0047	CcSEcCtD
Fesoterodine—Cough—Epirubicin—liver cancer	0.00117	0.00464	CcSEcCtD
Fesoterodine—Vision blurred—Doxorubicin—liver cancer	0.00117	0.00464	CcSEcCtD
Fesoterodine—Chest pain—Epirubicin—liver cancer	0.00114	0.00453	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00113	0.0045	CcSEcCtD
Fesoterodine—Dry mouth—Epirubicin—liver cancer	0.00112	0.00443	CcSEcCtD
Fesoterodine—Vertigo—Doxorubicin—liver cancer	0.00111	0.00442	CcSEcCtD
Fesoterodine—Confusional state—Epirubicin—liver cancer	0.0011	0.00438	CcSEcCtD
Fesoterodine—Palpitations—Doxorubicin—liver cancer	0.0011	0.00435	CcSEcCtD
Fesoterodine—Infection—Epirubicin—liver cancer	0.00109	0.00431	CcSEcCtD
Fesoterodine—Cough—Doxorubicin—liver cancer	0.00108	0.00429	CcSEcCtD
Fesoterodine—Nervous system disorder—Epirubicin—liver cancer	0.00107	0.00426	CcSEcCtD
Fesoterodine—Tachycardia—Epirubicin—liver cancer	0.00107	0.00424	CcSEcCtD
Fesoterodine—Skin disorder—Epirubicin—liver cancer	0.00106	0.00422	CcSEcCtD
Fesoterodine—Chest pain—Doxorubicin—liver cancer	0.00106	0.00419	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00105	0.00416	CcSEcCtD
Fesoterodine—Dry mouth—Doxorubicin—liver cancer	0.00103	0.0041	CcSEcCtD
Fesoterodine—Confusional state—Doxorubicin—liver cancer	0.00102	0.00405	CcSEcCtD
Fesoterodine—Infection—Doxorubicin—liver cancer	0.00101	0.00399	CcSEcCtD
Fesoterodine—Nervous system disorder—Doxorubicin—liver cancer	0.000993	0.00394	CcSEcCtD
Fesoterodine—Insomnia—Epirubicin—liver cancer	0.000989	0.00393	CcSEcCtD
Fesoterodine—Tachycardia—Doxorubicin—liver cancer	0.000988	0.00392	CcSEcCtD
Fesoterodine—Skin disorder—Doxorubicin—liver cancer	0.000983	0.0039	CcSEcCtD
Fesoterodine—Somnolence—Epirubicin—liver cancer	0.000973	0.00386	CcSEcCtD
Fesoterodine—Dyspepsia—Epirubicin—liver cancer	0.000963	0.00382	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Epirubicin—liver cancer	0.000944	0.00375	CcSEcCtD
Fesoterodine—Fatigue—Epirubicin—liver cancer	0.000943	0.00374	CcSEcCtD
Fesoterodine—Constipation—Epirubicin—liver cancer	0.000935	0.00371	CcSEcCtD
Fesoterodine—Insomnia—Doxorubicin—liver cancer	0.000915	0.00363	CcSEcCtD
Fesoterodine—Feeling abnormal—Epirubicin—liver cancer	0.000901	0.00358	CcSEcCtD
Fesoterodine—Somnolence—Doxorubicin—liver cancer	0.0009	0.00357	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Epirubicin—liver cancer	0.000895	0.00355	CcSEcCtD
Fesoterodine—Dyspepsia—Doxorubicin—liver cancer	0.000891	0.00354	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000874	0.00347	CcSEcCtD
Fesoterodine—Fatigue—Doxorubicin—liver cancer	0.000873	0.00346	CcSEcCtD
Fesoterodine—Urticaria—Epirubicin—liver cancer	0.000869	0.00345	CcSEcCtD
Fesoterodine—Constipation—Doxorubicin—liver cancer	0.000866	0.00343	CcSEcCtD
Fesoterodine—Abdominal pain—Epirubicin—liver cancer	0.000865	0.00343	CcSEcCtD
Fesoterodine—Feeling abnormal—Doxorubicin—liver cancer	0.000834	0.00331	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000828	0.00328	CcSEcCtD
Fesoterodine—Hypersensitivity—Epirubicin—liver cancer	0.000806	0.0032	CcSEcCtD
Fesoterodine—Urticaria—Doxorubicin—liver cancer	0.000804	0.00319	CcSEcCtD
Fesoterodine—Abdominal pain—Doxorubicin—liver cancer	0.0008	0.00318	CcSEcCtD
Fesoterodine—Asthenia—Epirubicin—liver cancer	0.000785	0.00311	CcSEcCtD
Fesoterodine—Pruritus—Epirubicin—liver cancer	0.000774	0.00307	CcSEcCtD
Fesoterodine—Diarrhoea—Epirubicin—liver cancer	0.000748	0.00297	CcSEcCtD
Fesoterodine—Hypersensitivity—Doxorubicin—liver cancer	0.000746	0.00296	CcSEcCtD
Fesoterodine—Asthenia—Doxorubicin—liver cancer	0.000726	0.00288	CcSEcCtD
Fesoterodine—Dizziness—Epirubicin—liver cancer	0.000723	0.00287	CcSEcCtD
Fesoterodine—Pruritus—Doxorubicin—liver cancer	0.000716	0.00284	CcSEcCtD
Fesoterodine—Diarrhoea—Doxorubicin—liver cancer	0.000693	0.00275	CcSEcCtD
Fesoterodine—Rash—Epirubicin—liver cancer	0.00069	0.00274	CcSEcCtD
Fesoterodine—Dermatitis—Epirubicin—liver cancer	0.000689	0.00273	CcSEcCtD
Fesoterodine—Headache—Epirubicin—liver cancer	0.000685	0.00272	CcSEcCtD
Fesoterodine—Dizziness—Doxorubicin—liver cancer	0.000669	0.00266	CcSEcCtD
Fesoterodine—Nausea—Epirubicin—liver cancer	0.00065	0.00258	CcSEcCtD
Fesoterodine—Rash—Doxorubicin—liver cancer	0.000638	0.00253	CcSEcCtD
Fesoterodine—Dermatitis—Doxorubicin—liver cancer	0.000638	0.00253	CcSEcCtD
Fesoterodine—Headache—Doxorubicin—liver cancer	0.000634	0.00252	CcSEcCtD
Fesoterodine—Nausea—Doxorubicin—liver cancer	0.000601	0.00239	CcSEcCtD
Fesoterodine—CHRM2—GPCR downstream signaling—IL2—liver cancer	4.79e-05	0.000267	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—PIK3CB—liver cancer	4.78e-05	0.000267	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—PIK3CA—liver cancer	4.77e-05	0.000267	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—SERPINE1—liver cancer	4.77e-05	0.000266	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTA1—liver cancer	4.75e-05	0.000265	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—PIK3CB—liver cancer	4.73e-05	0.000264	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—KRAS—liver cancer	4.72e-05	0.000264	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NAT2—liver cancer	4.7e-05	0.000262	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	4.69e-05	0.000262	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CYP2E1—liver cancer	4.68e-05	0.000262	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CYCS—liver cancer	4.65e-05	0.00026	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PIK3CD—liver cancer	4.62e-05	0.000258	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—PIK3CA—liver cancer	4.57e-05	0.000255	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—SERPINE1—liver cancer	4.57e-05	0.000255	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GGT1—liver cancer	4.56e-05	0.000255	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GOT1—liver cancer	4.56e-05	0.000255	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—KRAS—liver cancer	4.52e-05	0.000252	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ALDOB—liver cancer	4.5e-05	0.000252	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CG—liver cancer	4.41e-05	0.000246	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—IL2—liver cancer	4.4e-05	0.000246	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—IL2—liver cancer	4.39e-05	0.000245	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TERT—liver cancer	4.39e-05	0.000245	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CYCS—liver cancer	4.38e-05	0.000245	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TERT—liver cancer	4.37e-05	0.000244	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—IL2—liver cancer	4.35e-05	0.000243	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—PIK3CA—liver cancer	4.34e-05	0.000242	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TERT—liver cancer	4.33e-05	0.000242	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—RAF1—liver cancer	4.3e-05	0.00024	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GOT1—liver cancer	4.3e-05	0.00024	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GGT1—liver cancer	4.3e-05	0.00024	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CRABP1—liver cancer	4.3e-05	0.00024	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PPARG—liver cancer	4.25e-05	0.000238	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MTOR—liver cancer	4.2e-05	0.000235	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PIK3CB—liver cancer	4.2e-05	0.000235	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—PIK3CA—liver cancer	4.15e-05	0.000232	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—RAF1—liver cancer	4.12e-05	0.00023	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GSTP1—liver cancer	4.1e-05	0.000229	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—HMOX1—liver cancer	4.04e-05	0.000226	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MTOR—liver cancer	4.02e-05	0.000225	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PIK3CB—liver cancer	4.02e-05	0.000225	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—KDR—liver cancer	4.01e-05	0.000224	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—HRAS—liver cancer	4.01e-05	0.000224	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—KDR—liver cancer	4e-05	0.000223	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAPK14—liver cancer	3.99e-05	0.000223	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAPK14—liver cancer	3.97e-05	0.000222	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KDR—liver cancer	3.96e-05	0.000221	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CDKN1B—liver cancer	3.94e-05	0.00022	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAPK14—liver cancer	3.94e-05	0.00022	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—ESR1—liver cancer	3.91e-05	0.000218	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—AKT1—liver cancer	3.9e-05	0.000218	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—ESR1—liver cancer	3.9e-05	0.000218	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CD—liver cancer	3.87e-05	0.000216	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CASP3—liver cancer	3.86e-05	0.000216	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—F2—liver cancer	3.86e-05	0.000216	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GSTP1—liver cancer	3.86e-05	0.000216	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—ESR1—liver cancer	3.86e-05	0.000216	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL2—liver cancer	3.86e-05	0.000215	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—F2—liver cancer	3.85e-05	0.000215	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—HRAS—liver cancer	3.84e-05	0.000215	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—IL6—liver cancer	3.84e-05	0.000214	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—ALB—liver cancer	3.82e-05	0.000214	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—F2—liver cancer	3.81e-05	0.000213	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—HMOX1—liver cancer	3.81e-05	0.000213	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CDKN1B—liver cancer	3.78e-05	0.000211	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GSTM1—liver cancer	3.77e-05	0.00021	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CCND1—liver cancer	3.76e-05	0.00021	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—HPGDS—liver cancer	3.76e-05	0.00021	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—JUN—liver cancer	3.75e-05	0.00021	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—AKT1—liver cancer	3.74e-05	0.000209	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CTNNB1—liver cancer	3.72e-05	0.000208	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CASP3—liver cancer	3.7e-05	0.000207	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CG—liver cancer	3.7e-05	0.000206	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—APC—liver cancer	3.7e-05	0.000206	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL2—liver cancer	3.7e-05	0.000206	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CG—liver cancer	3.69e-05	0.000206	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—APC—liver cancer	3.69e-05	0.000206	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—IL6—liver cancer	3.68e-05	0.000205	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MMP9—liver cancer	3.65e-05	0.000204	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CG—liver cancer	3.65e-05	0.000204	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—APC—liver cancer	3.65e-05	0.000204	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CDKN1A—liver cancer	3.64e-05	0.000203	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCND1—liver cancer	3.6e-05	0.000201	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—JUN—liver cancer	3.59e-05	0.000201	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CYP1A1—liver cancer	3.57e-05	0.000199	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CTNNB1—liver cancer	3.57e-05	0.000199	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MAPK8—liver cancer	3.55e-05	0.000198	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GSTM1—liver cancer	3.55e-05	0.000198	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—AKT1—liver cancer	3.54e-05	0.000198	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MMP9—liver cancer	3.5e-05	0.000195	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CDKN1A—liver cancer	3.48e-05	0.000195	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—BRAF—liver cancer	3.48e-05	0.000194	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—BRAF—liver cancer	3.46e-05	0.000193	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—BRAF—liver cancer	3.43e-05	0.000192	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MAPK8—liver cancer	3.4e-05	0.00019	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—AKT1—liver cancer	3.39e-05	0.000189	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CB—liver cancer	3.38e-05	0.000189	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CYP1A1—liver cancer	3.36e-05	0.000188	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PSMD10—liver cancer	3.35e-05	0.000187	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PSMA4—liver cancer	3.35e-05	0.000187	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—MTHFR—liver cancer	3.33e-05	0.000186	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—VEGFA—liver cancer	3.28e-05	0.000183	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PPARA—liver cancer	3.27e-05	0.000182	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GOT2—liver cancer	3.26e-05	0.000182	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CD—liver cancer	3.25e-05	0.000181	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—STAT3—liver cancer	3.25e-05	0.000181	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CD—liver cancer	3.24e-05	0.000181	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—PIK3CA—liver cancer	3.22e-05	0.00018	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—SERPINE1—liver cancer	3.21e-05	0.00018	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—PIK3CA—liver cancer	3.21e-05	0.000179	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CD—liver cancer	3.21e-05	0.000179	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—SERPINE1—liver cancer	3.2e-05	0.000179	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—KRAS—liver cancer	3.18e-05	0.000178	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—PIK3CA—liver cancer	3.18e-05	0.000177	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SERPINE1—liver cancer	3.17e-05	0.000177	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—KRAS—liver cancer	3.17e-05	0.000177	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—KRAS—liver cancer	3.14e-05	0.000175	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—VEGFA—liver cancer	3.14e-05	0.000175	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—MTHFR—liver cancer	3.14e-05	0.000175	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—STAT3—liver cancer	3.11e-05	0.000174	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PPARA—liver cancer	3.08e-05	0.000172	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP2E1—liver cancer	3.06e-05	0.000171	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MYC—liver cancer	3.02e-05	0.000168	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TGFB1—liver cancer	3.01e-05	0.000168	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—PIK3CA—liver cancer	2.92e-05	0.000163	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—PIK3CA—liver cancer	2.91e-05	0.000163	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—RAF1—liver cancer	2.9e-05	0.000162	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—RAF1—liver cancer	2.89e-05	0.000162	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MYC—liver cancer	2.89e-05	0.000161	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—PIK3CA—liver cancer	2.89e-05	0.000161	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TGFB1—liver cancer	2.88e-05	0.000161	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYCS—liver cancer	2.86e-05	0.00016	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—RAF1—liver cancer	2.86e-05	0.00016	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MTOR—liver cancer	2.83e-05	0.000158	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CB—liver cancer	2.83e-05	0.000158	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MTOR—liver cancer	2.82e-05	0.000158	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CB—liver cancer	2.82e-05	0.000158	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GOT1—liver cancer	2.81e-05	0.000157	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GGT1—liver cancer	2.81e-05	0.000157	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CG—liver cancer	2.8e-05	0.000156	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MTOR—liver cancer	2.8e-05	0.000156	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CB—liver cancer	2.8e-05	0.000156	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—KRAS—liver cancer	2.79e-05	0.000156	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—HRAS—liver cancer	2.7e-05	0.000151	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PPARG—liver cancer	2.7e-05	0.000151	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—HRAS—liver cancer	2.7e-05	0.000151	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—HRAS—liver cancer	2.67e-05	0.000149	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—KRAS—liver cancer	2.67e-05	0.000149	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CDKN1B—liver cancer	2.66e-05	0.000148	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CDKN1B—liver cancer	2.65e-05	0.000148	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CG—liver cancer	2.64e-05	0.000147	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—AKT1—liver cancer	2.63e-05	0.000147	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CDKN1B—liver cancer	2.62e-05	0.000147	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—AKT1—liver cancer	2.62e-05	0.000146	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CASP3—liver cancer	2.61e-05	0.000146	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL2—liver cancer	2.6e-05	0.000145	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CASP3—liver cancer	2.6e-05	0.000145	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—AKT1—liver cancer	2.6e-05	0.000145	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL2—liver cancer	2.59e-05	0.000145	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—IL6—liver cancer	2.59e-05	0.000145	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—IL6—liver cancer	2.58e-05	0.000144	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CASP3—liver cancer	2.57e-05	0.000144	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL2—liver cancer	2.57e-05	0.000143	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PIK3CA—liver cancer	2.56e-05	0.000143	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—IL6—liver cancer	2.56e-05	0.000143	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PPARG—liver cancer	2.54e-05	0.000142	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCND1—liver cancer	2.54e-05	0.000142	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—JUN—liver cancer	2.53e-05	0.000141	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCND1—liver cancer	2.53e-05	0.000141	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTP1—liver cancer	2.53e-05	0.000141	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—JUN—liver cancer	2.52e-05	0.000141	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CTNNB1—liver cancer	2.51e-05	0.00014	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCND1—liver cancer	2.5e-05	0.00014	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CTNNB1—liver cancer	2.5e-05	0.00014	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—JUN—liver cancer	2.5e-05	0.00014	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—HMOX1—liver cancer	2.49e-05	0.000139	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CTNNB1—liver cancer	2.48e-05	0.000138	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TP53—liver cancer	2.48e-05	0.000138	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MMP9—liver cancer	2.46e-05	0.000137	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CD—liver cancer	2.46e-05	0.000137	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MMP9—liver cancer	2.45e-05	0.000137	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CDKN1A—liver cancer	2.45e-05	0.000137	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PIK3CA—liver cancer	2.45e-05	0.000137	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CDKN1A—liver cancer	2.45e-05	0.000137	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MMP9—liver cancer	2.43e-05	0.000136	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ALB—liver cancer	2.43e-05	0.000136	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CDKN1A—liver cancer	2.42e-05	0.000135	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAPK8—liver cancer	2.39e-05	0.000134	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—AKT1—liver cancer	2.39e-05	0.000133	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAPK8—liver cancer	2.39e-05	0.000133	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—AKT1—liver cancer	2.38e-05	0.000133	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TP53—liver cancer	2.37e-05	0.000132	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—HRAS—liver cancer	2.37e-05	0.000132	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAPK8—liver cancer	2.36e-05	0.000132	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—AKT1—liver cancer	2.36e-05	0.000132	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTM1—liver cancer	2.32e-05	0.00013	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CD—liver cancer	2.32e-05	0.000129	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ALB—liver cancer	2.29e-05	0.000128	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—HRAS—liver cancer	2.27e-05	0.000127	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL6—liver cancer	2.27e-05	0.000127	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—VEGFA—liver cancer	2.21e-05	0.000123	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—VEGFA—liver cancer	2.2e-05	0.000123	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP1A1—liver cancer	2.2e-05	0.000123	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—STAT3—liver cancer	2.19e-05	0.000122	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—VEGFA—liver cancer	2.18e-05	0.000122	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—STAT3—liver cancer	2.18e-05	0.000122	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL6—liver cancer	2.17e-05	0.000121	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—STAT3—liver cancer	2.16e-05	0.000121	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CB—liver cancer	2.14e-05	0.00012	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—AKT1—liver cancer	2.09e-05	0.000117	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CA—liver cancer	2.06e-05	0.000115	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—MTHFR—liver cancer	2.05e-05	0.000115	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MYC—liver cancer	2.03e-05	0.000114	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TGFB1—liver cancer	2.03e-05	0.000113	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MYC—liver cancer	2.03e-05	0.000113	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TGFB1—liver cancer	2.02e-05	0.000113	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CB—liver cancer	2.02e-05	0.000113	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PPARA—liver cancer	2.01e-05	0.000112	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MYC—liver cancer	2.01e-05	0.000112	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—AKT1—liver cancer	2e-05	0.000112	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TGFB1—liver cancer	2e-05	0.000112	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—KRAS—liver cancer	1.88e-05	0.000105	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—KRAS—liver cancer	1.87e-05	0.000105	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KRAS—liver cancer	1.86e-05	0.000104	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CA—liver cancer	1.73e-05	9.64e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CG—liver cancer	1.72e-05	9.62e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CA—liver cancer	1.72e-05	9.61e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CA—liver cancer	1.7e-05	9.52e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—AKT1—liver cancer	1.68e-05	9.39e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TP53—liver cancer	1.67e-05	9.33e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TP53—liver cancer	1.67e-05	9.3e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PPARG—liver cancer	1.66e-05	9.29e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TP53—liver cancer	1.65e-05	9.21e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—HRAS—liver cancer	1.6e-05	8.92e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—HRAS—liver cancer	1.59e-05	8.89e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—HRAS—liver cancer	1.58e-05	8.81e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL6—liver cancer	1.53e-05	8.54e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL6—liver cancer	1.52e-05	8.51e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CD—liver cancer	1.51e-05	8.46e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL6—liver cancer	1.51e-05	8.43e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ALB—liver cancer	1.5e-05	8.35e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—AKT1—liver cancer	1.41e-05	7.88e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—AKT1—liver cancer	1.41e-05	7.85e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—AKT1—liver cancer	1.39e-05	7.78e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CB—liver cancer	1.32e-05	7.37e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CA—liver cancer	1.31e-05	7.29e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CA—liver cancer	1.23e-05	6.87e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—AKT1—liver cancer	1.07e-05	5.96e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—AKT1—liver cancer	1.01e-05	5.62e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CA—liver cancer	8.05e-06	4.49e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—AKT1—liver cancer	6.57e-06	3.67e-05	CbGpPWpGaD
